Inflexion has completed an investment in Pangaea Laboratories (Pangaea), a global beauty business and owner of the fast-growing Medik8 skincare brand.
The investment is being made by Inflexion Buyout Fund V, Inflexion’s dedicated mid‐market fund.
Founder-led since 1999, Pangaea is an innovative and fully vertically integrated firm with two facilities in Hertfordshire, where Medik8’s products are developed and manufactured in-house.
Medik8 is a premium skincare brand focused on science-based, skin-ageing products. With a strong heritage in the international professional channel and a growing online presence, Medik8 is committed to ethical manufacturing and sustainability. Medik8 is focused on enhancing its strong relationships within the professional beauty industry while growing digital channels in new international markets.
Elliot Isaacs, Founder of Medik8, says: “In the last three years, the brand has experienced phenomenal growth as the skincare consumer has become more knowledgeable and moved towards science and ingredients. We are thrilled to be partnering with Inflexion who have the passion and expertise to help us accelerate the brand’s international ambitions. Crucially, Inflexion have been unwavering in their support for our amazing team and professional-led heritage. We could not be more excited about the future.”
Simon Turner, Managing Partner of Inflexion, says: “Medik8’s science-based approach to skincare combined with its sustainability credentials make it an incredibly impressive business. We look forward to working closely with the whole team to scale the business further through enhancing their digital routes to market, and by supporting their continued innovation, new product launches and international expansion.”
